Medicaments
    2.
    发明授权
    Medicaments 失效
    药剂

    公开(公告)号:US5221687A

    公开(公告)日:1993-06-22

    申请号:US934307

    申请日:1992-08-25

    摘要: The invention relates to the use of compounds of formula (I) ##STR1## wherein Im represents an imidazolyl group of formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenylC.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl, phenoxymethyl, --CO.sub.2 R.sup.5, --COR.sup.5, --CONR.sup.5 R.sup.6 or --SO.sub.2 R.sup.5 (wherein R.sup.5 and R.sup.6, which may be the same or different, each represents a hydrogen atom, a C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl group, or a phenyl or phenylC.sub.1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C.sub.1-4 alkyl, C.sub.1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R.sup.5 does not represent a hydrogen atom when R.sup.1 represents a group --CO.sub.2 R.sup.5 or --SO.sub.2 R.sup.5);one of the groups represented by R.sup.2, R.sup.3 and R4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenylC.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group;and n represents 2 or 3,and physiologically acceptable salts and solvates thereof for the manufacture of a medicament for the treatment of depression.

    摘要翻译: 本发明涉及式(I)化合物其中Im表示下式的咪唑基,R1表示氢原子或选自C 1-6烷基,C 3-6烯基, C 3-10炔基,C 3-7环烷基,C 3-7环烷基C 1-4烷基,苯基,苯基C 1-3烷基,苯基甲氧基甲基,苯氧基乙基,苯氧基甲基,-CO 2 R 5,-COR 5,-CONR 5 R 6或-SO 2 R 5(其中R 5和R 6可以相同或不同 各自表示氢原子,C 1-6烷基或C 3-7环烷基,或苯基或苯基C 1-4烷基,其中苯基任选被一个或多个C 1-4烷基,C 1-4烷氧基或羟基或卤素 原子,条件是当R 1表示-CO 2 R 5或-SO 2 R 5基团时,R 5不表示氢原子); 由R 2,R 3和R 4表示的基团之一是氢原子或C 1-6烷基,C 3-7环烷基,C 3-6烯基,苯基或苯基C 1-3烷基,其它两个基团可以相同或 不同,代表氢原子或C1-6烷基; 和n表示2或3,以及其生理上可接受的盐和溶剂合物,用于制备用于治疗抑郁症的药物。

    Medicaments
    3.
    发明授权
    Medicaments 失效
    药剂

    公开(公告)号:US5229407A

    公开(公告)日:1993-07-20

    申请号:US911395

    申请日:1992-07-10

    摘要: The invention relates to the use of compounds of formula (I) ##STR1## wherein Im represents an imidazolyl group of formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenylC.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl, phenoxymethyl, --CO.sub.2 R.sup.5, --COR.sup.5, --CONR.sup.5 R.sup.6 or --SO.sub.2 R.sup.5 (wherein R.sup.5 and R.sup.6, which may be the same or different, each represents a hydrogen atom, a C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl group, or a phenyl or phenylC.sub.1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C.sub.1-4 alkyl, C.sub.1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R.sup.5 does not represent a hydrogen atom when R.sup.1 represents a group --CO.sub.2 R.sup.5 or --SO.sub.2 R.sup.5);one of the groups represented by R.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenylC.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group;and n represents 2 or 3,and physiologically acceptable salts and solvates thereof for the manufacture of a medicament for the treatment of a cognitive disorder.

    摘要翻译: 本发明涉及式(I)化合物其中Im表示下式的咪唑基,R1表示氢原子或选自C 1-6烷基,C 3-6烯基, C 3-10炔基,C 3-7环烷基,C 3-7环烷基C 1-4烷基,苯基,苯基C 1-3烷基,苯基甲氧基甲基,苯氧基乙基,苯氧基甲基,-CO 2 R 5,-COR 5,-CONR 5 R 6或-SO 2 R 5(其中R 5和R 6可以相同或不同 各自表示氢原子,C 1-6烷基或C 3-7环烷基,或苯基或苯基C 1-4烷基,其中苯基任选被一个或多个C 1-4烷基,C 1-4烷氧基或羟基或卤素 原子,条件是当R 1表示-CO 2 R 5或-SO 2 R 5基团时,R 5不表示氢原子); 由R 2,R 3和R 4表示的基团之一是氢原子或C 1-6烷基,C 3-7环烷基,C 3-6烯基,苯基或苯基C 1-3烷基,其它两个基团可以相同或 不同,代表氢原子或C1-6烷基; 和n表示2或3,以及其生理上可接受的盐和溶剂合物,用于制备用于治疗认知障碍的药物。

    Medicaments
    5.
    发明授权
    Medicaments 失效
    药剂

    公开(公告)号:US5276050A

    公开(公告)日:1994-01-04

    申请号:US908329

    申请日:1992-07-06

    IPC分类号: A61K31/415

    CPC分类号: A61K31/415

    摘要: The invention relates to the use of compounds of the general formula (I) ##STR1## and physiologically acceptable salts and solvates thereof, in which Im represents an imidazolyl group of formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenylC.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl, phenoxymethyl, --CO.sub.2 R.sup.5, --COR.sup.5, --CONR.sup.5 R.sup.6 or --SO.sub.2 R.sup.5 (wherein R.sup.5 and R.sup.6, which may be the same or different each represents a hydrogen atom, a C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl group, or a phenyl or phenylC.sub.1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C.sub.1-4 alkyl, C.sub.1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R.sup.5 does not represent a hydrogen atom when R.sup.1 represents a group --CO.sub.2 R.sup.5 or --SO.sub.2 R.sup.5);one of the groups represented by R.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenylC.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group;and n represents 2 or 3,for the treatment of a condition involving excessive eating, for example bulimia.

    摘要翻译: 本发明涉及通式(I)化合物(Ⅰ)及其生理上可接受的盐和溶剂化物,其中Im表示下式的咪唑基:其中R1表示 氢原子或选自C 1-6烷基,C 3-6烯基,C 3-10炔基,C 3-7环烷基,C 3-7环烷基C 1-4烷基,苯基,苯基C 1-3烷基,苯基甲氧基甲基,苯氧基乙基,苯氧基甲基,-CO 2 R 5,-COR 5,-CONR 5 R 6或 -SO 2 R 5(其中R 5和R 6可以相同或不同,各自表示氢原子,C 1-6烷基或C 3-7环烷基或苯基或苯基C 1-4烷基,其中苯基任选被一个 或更多C 1-4烷基,C 1-4烷氧基或羟基或卤素原子,条件是当R 1表示-CO 2 R 5或-SO 2 R 5基团时,R 5不表示氢原子); 由R 2,R 3和R 4表示的基团之一是氢原子或C 1-6烷基,C 3-7环烷基,C 3-6烯基,苯基或苯基C 1-3烷基,其它两个基团可以相同或 不同的是氢原子或C1-6烷基; n表示2或3,用于治疗涉及过度饮食的病症,例如贪食症。

    Indole derivatives
    6.
    发明授权

    公开(公告)号:US5026722A

    公开(公告)日:1991-06-25

    申请号:US366462

    申请日:1989-06-15

    CPC分类号: C07D403/12

    摘要: The invention relates to indole derivatives of the general formula (I) ##STR1## wherein Im represents an imidazolyl group of the formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl or phenylC.sub.1-3 alkyl;R.sup.2 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-7 cycloalkyl, phenyl or phenylC.sub.1-3 alkyl;X represents an oxygen atom or the group NR.sup.3 (where R.sup.3 represents a hydrogen atom or a C.sub.1-6 alkyl group);one of the groups represented by R.sup.4, R.sup.5 and R.sup.6 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenylC.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group;Q represents a hydrogen or a halogen atom, or a hydroxy, C.sub.1-4 alkoxy, phenylC.sub.1-3 alkoxy or C.sub.1-6 alkyl group or a group -NR.sup.7 R.sup.8 or -CONR.sup.7 R.sup.8 (wherein R.sup.7 and R.sup.8, which may be the same or different, each represents a hydrogen atom or a C.sub.1-4 alkyl or C.sub.3-4 alkenyl group, or together with the nitrogen atom to which they are attached form a saturated 5 to 7 membered ring);and physiologically acceptable salts and solvates thereof.The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT.sub.3 receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.

    Ketone derivatives
    8.
    发明授权
    Ketone derivatives 失效
    酮衍生物

    公开(公告)号:US5019586A

    公开(公告)日:1991-05-28

    申请号:US440880

    申请日:1989-11-24

    摘要: The present invention provides ketones of the general formula (I): ##STR1## and physiologically acceptable salts and solvates thereof, wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom or a C.sub.1-6 alkyl group;Im represents an imidazolyl group of formula: ##STR2## wherein one of the groups represented by R.sup.3, R.sup.4 and R.sup.5 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenylC.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group; and p0 A is a group of the formula (a), (b), (c), (d), (e), (f) or (g): ##STR3## and when A is the group (g), the group --COCR.sup.1 R.sup.2 CH.sub.2 Im is attached at the 2- or 4- position of the indole moiety.The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT.sub.3 receptors and are useful, for example, in the treatment of psychotic disorders, anxiety and nausea and vomiting.

    摘要翻译: 本发明提供通式(I)的酮:其中R 1和R 2可以相同或不同,表示氢原子或C 1-6烷基 组; Im表示下式的咪唑基:其中,由R 3,R 4和R 5表示的基团之一是氢原子或C 1-6烷基,C 3-7环烷基,C 3-6烯基,苯基或苯基C 1-3烷基, 可以相同或不同的其它两个基团表示氢原子或C 1-6烷基; (a),(b),(c),(d),(e),(f)或(g)中的一个基团:(a) (c)<图像>(d)(e)(f)(g),当A是组(g)时,组-COCR1R2CH2Im被附加在2-或 吲哚部分的4-位。 这些化合物是5-HT在5-HT 3受体上的作用的有效和选择性拮抗剂,可用于例如治疗精神病,焦虑和恶心和呕吐。